Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract
- 1 July 1994
- Vol. 74 (1) , 123-133
- https://doi.org/10.1002/1097-0142(19940701)74:1<123::aid-cncr2820740121>3.0.co;2-t
Abstract
Background. Prognostic factors for patients with disseminated transitional cell carcinoma of the urothelium (TCC) has been examined only in patients selected for studies with chemotherapy. This study was performed to determine important prognostic factors in patients with disseminated TCC and evaluate the impact of chemotherapy. Methods. The prognostic factors for survival were analyzed in 240 patients with disseminated TCC admitted from 1976 to 1992. Information on prior medical history, baseline variables, and treatment were related to survival after dissemination. Both univariate and multivariate analyses were performed to identify factors of independent importance. Results. Univariate analyses indicated that performance status; hemoglobin; leukocyte count; platelet count; concentrations of serum creatinine, aspartate aminotransferase, lactate dehydrogenase, and alkaline phosphatase; hydronephrosis; bone metastases; disease extension; and chemotherapy were related significantly to survival. Multivariate analysis demonstrated that a good performance status, a normal alkaline phosphatase concentration, and a normal serum creatinine concentration were independent prognosticators for long survival. When chemotherapy was included in the analysis, it was found to be the most important independent prognostic factor in conjunction with alkaline phosphatase and performance status. Conclusion. This study has established the importance of performance status and alkaline phosphatase as the most important prognostic factors of survival in patients with disseminated TCC regardless of treatment. Chemotherapy was found to be an independent prognostic variable that indicates a possible prolongation of survival in patients receiving chemotherapy.Keywords
This publication has 15 references indexed in Scilit:
- A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urotheliumEuropean Journal Of Cancer, 1993
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1992
- Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapyCancer, 1991
- Analyses of Factors Affecting the Outcome of Combination Chemotherapy in Patients with Advanced Bladder CancerEuropean Urology, 1991
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.Journal of Clinical Oncology, 1990
- Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseCancer, 1989
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Chemotherapy for Transitional Cell Carcinoma: The Princess Margaret Hospital ExperienceJournal of Urology, 1989
- Multivariate survival analysis using Cox's regression modelHepatology, 1987
- Metastases from transitional cell carcinoma of urinary bladderUrology, 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958